OxfordBiomedica

Home
About
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry…
- Mission and strategy
  At Oxford BioMedica, our mission is to build a valuable, profitable biopharmaceu…
- History
  From Oxford University spin-out to a leading company in gene, cell and immunothe…
- Meet the team
- Careers
  Our vision: Oxford BioMedica is a leading company in gene and cell therapy, and…
- Meet us - conferences
  The management team regularly attends key industry conferences to meet investors and potential partners. Our scientists also represent Oxford BioMedica at key scientific and medical congresses.
R&D
Building on a unique platform that combines our intellectual property, know-how and facilities, our business is now strongly positioned to succeed in the evolved gene and cell therapy sector.
- What is gene and cell therapy?
  Gene and cell therapy is at the forefront of medical science and has the potential to transform the treatment of some of the most challenging diseases. Gene and cell therapy is the treatment of disease by delivering therapeutic DNA into a p…
- Pipeline
- Platform technologies
  - The LentiVector^® platform
    Why use a lentiviral vector?
  - 5T4 Tumour Antigen
    The 5T4 tumour antigen is a unique protein found on most common types of solid cancer, which makes it a potentially valuable target for novel anti-cancer interventions. The 5T4 antigen was discovered by scientists at Cancer Research UK (for…
  - CAR-T cell therapy
    The Group is developing a product which combines both its LentiVector® and 5T4 technology platforms. The product is based on a gene modified autologous T-cell which is engineered using a lentiviral vector to express an antibody against 5T4…
- Products
  - RetinoStat®
    A novel gene-based treatment for neovascular "wet" age-related macular degeneration (AMD).
  - SAR 422459
    A gene-based therapy for the treatment of Stargardt disease.
  - SAR 421869
    A gene-based therapy for the treatment of Usher syndrome type 1B.
  - EncorStat®
    A gene-based treatment for the prevention of corneal graft rejection.
  - Glaucoma-GT
    A gene based treatment for the treatment of chronic glaucoma.
  - OXB-102 | ProSavin®
    OXB 102 / ProSavin® is a gene-based treatment for Parkinson's disease, a chronic degenerative neurological condition.
  - MoNuDin®
    MoNuDin® is being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS) which is the most common form of motor neurone disease.
  - TroVax®
    TroVax® (MVA-5T4) is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen which is present on most solid tumours.
  - Anti-5T4 antibody
    The 5T4-targeted antibody therapy is a humanised monoclonal antibody linked to a potent anti-cancer agent.
- Clinical trials
  Oxford BioMedica is currently recruiting for clinical trials as detailed below. For further information, please visit the www.clinicaltrials.gov website or contact your doctor or primary healthcare professional. If you are currently par…
- Key publications
  Below is a selection of key publications of interest. A more comprehensive list can be provided on request.
Partnerships
Our strategy is to maximise the potential of our technologies and product candid…
- Current partnerships
  - Our partners
  - Our licensees
- Opportunities
  Oxford BioMedica is seeking development and commercialisation partners for the following products. Click on each product for more information.
- Intellectual property
  Oxford BioMedica has built an extensive patent portfolio that provides comprehensive protection for gene-based delivery technologies and their therapeutic application. This portfolio contains over fifty patent families which are either own…
Manufacturing
Oxford BioMedica is a world leader in the development of lentiviral vector-based…
- OXB Solutions microsite
Investors
Oxford BioMedica has strong fundamentals as an investment proposition.
- Analyst coverage
  The following analysts cover Oxford BioMedica:
- Key financial information
- Share price information
  - Share price chart
- Regulatory news
- Shareholder meetings
- Corporate governance
  The policy of the Board is to manage the affairs of Oxford BioMedica to the high…
  - Board committees
- Warning to shareholders
  In recent years, many companies have become aware that their shareholders have received unsolicited phone calls or correspondence concerning investment matters. These are typically from overseas based ‘brokers’ who target UK shareholder…
- Investor contacts
- Financial calendar
- Registrars
  All administrative enquiries relating to shareholdings and requests to receive corporate documents by email should, in the first instance, be directed to Capita Registrars.
- Financial reports
- Upcoming conferences
Media
CSR
At Oxford BioMedica we recognise our obligation to behave as a responsible corpo…
Contact

World-leading expertise in Gene and Cell Therapy

Investor centre

Presentations Pipeline Media

News
Twitter
YouTube

More news

RT @andrew_ward1: Boris floats £10bn fund to support London's "cornucopia" of science & close gap with booming New York biotech market http…

25th June, 2015 09:32am

See our YouTube channel

Email alerts

We have several mailing lists which you can subscribe to, click here to register

Quick links

Legal

Cookies

This website uses cookies to improve user experience. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. Read more about our cookie policy here.

Follow us

Oxford BioMedica plc

Windrush Court
Transport Way
Oxford
OX4 6LT
United Kingdom

Telephone: +44 (0) 1865 783 000
Fax: +44 (0) 1865 783 001
Email: enquiries@oxfordbiomedica.co.uk

Website by thinkerdoer

twitter linkedin youtube flickr RSS email